31 results about "Malignant effusion" patented technology

The invention discloses a target MYO9B related to malignant pleural effusion and application of the target MYO9B. The invention further discloses any of the following 1)-5) application: 1) application of a substance inhibiting the activity of MYO9B protein in preparing a product for treating or assisting treatment of malignant pleural effusion; 2) application of the substance inhibiting the activity of MYO9B protein in preparing a product for lowering or reducing the amount of pleural effusion in patients with malignant pleural effusion; 3) application of a substance that inhibits or silences MYO9B gene expression in preparing the product for treating or assisting treatment of malignant pleural effusion; 4) application of the substance that inhibits or silences MYO9B gene expression in preparing the product for lowering or reducing the amount of pleural effusion in patients with malignant pleural effusion; 5) application of MYO9B protein and related signaling pathways thereof as targets in developing or designing the product of treating or assisting treatment of malignant pleural effusion.

The invention relates to an isolated culture method of tumor-specific T cells and a product obtained by the isolated culture method. The isolated culture method comprises the following steps: firstly,pretreating peripheral blood of a tumor patient, then separating mononuclear cells in the peripheral blood, then separating PD-1 positive mononuclear cells, and finally amplifying the PD-1 positive mononuclear cells to obtain the tumor-specific T cells. According to the method for isolated culture of the tumor-specific T cells, the initial material is peripheral blood of the tumor patient, tumortissue or malignant pleural effusion of the patient does not need to be used as the material, materials are more convenient to obtain, blood sampling can be conveniently conducted on almost all tumorpatients, and large trauma is avoided; the finally obtained T cells are high in tumor specificity and contain CD4 positive T cells and CD8 positive T cells at the same time; the method is simple in operation process and short in required time.

The invention discloses a cancer therapeutic medicine capable of killing medicine-resistant tumor cells and tumor stem cells in chemicotherapy and an application thereof. The medicine is characterized by comprising the following components: the liquid medicine in every 100 milliliters contains 2-10ml of absolute ethyl alcohol, 40-50mg of cis-platinum complexes and 90-98ml of sterile water. The medicine is mainly used for local injection of tumors or intravesical therapy of chest, abdomen, pericardial cavity malignant effusion or aerosol inhalation therapy of lung tumors, and is suitable for the therapy of various solid tumors such as lung cancer, liver cancer, pancreatic cancer, ovarian cancer, cervical cancer, mammary cancer, retroperitoneal tumor or retroperitoneal lymph node metastasis, cardia cancer, gastrointestinal malignant cancer, soft tissue sarcoma, glioma and head and neck neoplasm and the medicine-resistant or medicine-sensitive tumor therapy with chest, abdomen, pericardial cavity malignant effusion.

The invention relates to an inoculation liquid composition and a method for building a malignant pleural effusion sourced xenotransplantation tumor animal model by using the inoculation liquid composition. The inoculation liquid provided by the invention contains the following ingredients including Hank' blanace salt buffer solution, fetal calf serum, basement membrane substrate glue and ROCK protein inhibitor. The method for building the malignant pleural effusion sourced xenotransplantation tumor animal model provided by the invention comprises the steps of collecting a clinic malignant pleural effusion sample, enriching tumor cells, using inoculation liquid suspension cells provided by the invention, and inoculating the cells into an animal so as to form xenotransplantation tumor. The model building method provided by the invention has the advantages that simplicity is easy; the implementation is easy; the tumor forming rate is high, so that the method can be used for medicine screening and mechanism study of various kinds of cancer with malignant pleural effusion.

The invention relates to a method for preparing high-killing-activity TIL cells in batches from malignant pleuroperitoneal fluid. The method comprises the steps that (338.6+ / -134.2)*10<8>(n=25) TIL cells can be obtained when culture is performed for 21-28 d, the cells are amplified by 179.6+ / -24.2 times, wherein, CD3+cells account for 98.61%+ / -3.22%, CD3+CD8+cells account for 74.56%+ / -5.19%, CD3+CD4+cells account for 27.42%+ / -6.35%, CD3+CD56+cells account for 51.88%+ / -7.49%, and CD4+CD25+FoxP3+ Tregs cells only account for 3.27%+ / -1.75%. The killing activity for tumor cells can reach 66.54%+ / -5.18% (according to a 4h51Cr release method, the effect / target ratio is equal to 40:1).

The invention provides a medicine composite for treating malignant pleural effusion. The medicine composite is prepared with, by weight, 2-18 parts of American ginseng, 4-30 parts of pseudo-ginseng, 2-18 parts of pepperweed seeds, 3-21 parts of pyrrosia lingua, 2-8 parts of seeds of zanthoxylom bungeanum maxim, 10-50 parts of cynanchum paniculatum, 5-25 parts of snake gourd fruits, 10-50 parts of raw radix astragalis, 2-18 parts of rhizoma alismatis, 3-21 parts of rhizoma atractylodis macrocephalae and 2-12 parts of Chinese dates. All ingredients cooperate with one another, the medicine composite is placed in water for dissolution before drinking and is effective in warming the Yang, smoothing the Qi, communicating the Yang and the Qi, excreting the dampness and tonifying the spleen, and all medicine cooperate to achieve that the Yang is warmed and the effusion is relieved. Clinical tests prove that the medicine composite is capable of effectively treating the malignant pleural effusion.

The invention provides an analysis method for a volatile organic compound in pleural effusion. The method comprises the steps of headspace solid phase microextraction, cold trap focusing and gas chromatographic and mass spectrometry combination. The method with the combination of the cold trap focusing and gas chromatographic and mass spectrometry combination on the basis of the headspace solid phase microextraction technology can rapidly and accurately analyze the volatile organic compound in the pleural effusion. According to the analysis method, extraction, enrichment and sample introduction are integrated into headspace solid phase microextraction, operation is easy and convenient, no complex pretreatment process is needed, complex matrix interference of biological samples is eliminated, and component information distortion in samples is not caused; due to the cold trap focusing technology, the high-volatility organic compound in the pleural effusion is condensed and secondarily analyzed at low temperature and effectively separated on the proper chromatographic condition. According to the analysis method, the volatile organic compound in the pleural effusion can be rapidly detected, quanlitative and semi-quantitative analysis is performed, and the analysis method is of great importance in distinguishing benign and malignant pleural effusion and even screening lung cancer markers by applying difference analysis.

The present invention relates to the use of an immunoregulatory composition in treating malignant effusion, wherein the composition has the function of immune regulation. It specifically relates to the use of the composition in the preparation of medicines for alleviating and treating malignant effusion, wherein the composition contains polyriboinosine-polyribocytidylic acid (PIC). The composition may further comprise at least one stabilizer and calcium ions, anticancer agents or other pharmaceutically acceptable carriers.

The invention belongs to the technical field of detection methods for malignant pleural effusion, and specifically relates to a method using CD14+? CD163+ cells to identify malignant pleural effusions. The method comprises three steps of extracting mononuclear cells, antibody labeling, and performing immunophenotype analysis by flow cytometry. Compared with the existing technology, this method has the advantages of simplicity, rapidity, high sensitivity, and high specificity; at the same time, this method can reduce the interference of human subjective factors, is more objective, and can make early judgments on patients with potential malignant pleural effusion , identification, so as to provide convenience for subsequent timely intervention and treatment.